Galmed Pharmaceuticals Book Value Per Share Growth & History (GLMD)
Galmed Pharmaceuticals's book value per share was $19.18 for fiscal 2025.
View full Galmed Pharmaceuticals company overviewGalmed Pharmaceuticals annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $19.18 | -$59.27 | −75.55% |
| 2024 | 2024-12-31 | $78.45 | -$115.07 | −59.46% |
| 2023 | 2023-12-31 | $193.52 | $130.07 | +204.99% |
| 2022 | 2022-12-31 | $63.45 | -$82.42 | −56.50% |
| 2021 | 2021-12-31 | $145.87 | -$102.58 | −41.29% |
| 2020 | 2020-12-31 | $248.45 | -$148.08 | −37.34% |
| 2019 | 2019-12-31 | $396.53 | -$105.27 | −20.98% |
| 2018 | 2018-12-31 | $501.80 | $370.49 | +282.16% |
| 2017 | 2017-12-31 | $131.30 | $21.91 | +20.03% |
| 2016 | 2016-12-31 | $109.39 | -$123.52 | −53.03% |
| 2015 | 2015-12-31 | $232.91 | -$106.61 | −31.40% |
| 2014 | 2014-12-31 | $339.52 | $24,378.95 | — |
| 2013 | 2013-12-31 | -$24,039.43 | -$23,991.51 | — |
| 2012 | 2012-12-31 | -$47.92 | — | — |
Galmed Pharmaceuticals quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.72 | -$18.24 | −58.91% |
| Q1 2026 | 2026-03-31 | $16.91 | $9.43 | +126.21% |
| Q4 2025 | 2025-12-31 | $19.18 | -$59.27 | −75.55% |
| Q3 2025 | 2025-09-30 | $27.90 | — | — |
| Q2 2025 | 2025-06-30 | $30.96 | $16.13 | +108.78% |
| Q1 2025 | 2025-03-31 | $7.47 | — | — |
| Q4 2024 | 2024-12-31 | $78.45 | -$115.07 | −59.46% |
| Q2 2024 | 2024-06-30 | $14.83 | -$35.42 | −70.49% |
| Q4 2023 | 2023-12-31 | $193.52 | $130.07 | +204.99% |
| Q2 2023 | 2023-06-30 | $50.25 | -$48.82 | −49.28% |
| Q4 2022 | 2022-12-31 | $63.45 | -$82.42 | −56.50% |
| Q2 2022 | 2022-06-30 | $99.07 | -$116.21 | −53.98% |
| Q4 2021 | 2021-12-31 | $145.87 | -$102.58 | −41.29% |
| Q2 2021 | 2021-06-30 | $215.27 | -$124.44 | −36.63% |
| Q4 2020 | 2020-12-31 | $248.45 | -$148.08 | −37.34% |
| Q2 2020 | 2020-06-30 | $339.72 | -$122.68 | −26.53% |
| Q4 2019 | 2019-12-31 | $396.53 | -$105.27 | −20.98% |
| Q2 2019 | 2019-06-30 | $462.40 | -$60.02 | −11.49% |
| Q4 2018 | 2018-12-31 | $501.80 | $370.49 | +282.16% |
| Q2 2018 | 2018-06-30 | $522.42 | $461.12 | +752.22% |
| Q4 2017 | 2017-12-31 | $131.30 | $21.91 | +20.03% |
| Q2 2017 | 2017-06-30 | $61.30 | -$94.62 | −60.68% |
| Q4 2016 | 2016-12-31 | $109.39 | -$123.52 | −53.03% |
| Q2 2016 | 2016-06-30 | $155.92 | — | — |
| Q4 2015 | 2015-12-31 | $232.91 | -$106.61 | −31.40% |
| Q4 2014 | 2014-12-31 | $339.52 | — | — |
Galmed Pharmaceuticals book value per share trends
Over the last five fiscal years, Galmed Pharmaceuticals's book value per share decreased from $248.45 to $19.18, a change of -$229.26. The latest reported quarter, Q2 2026, shows $12.72.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Galmed Pharmaceuticals source filings ↗